 |
|
Current Therapy for Brain Tumors
Back to the Future
William R. Shapiro, MD
Arch Neurol. 1999;56:429-432.
In the last 30 years, while considerable progress has been made in laboratory research of malignant gliomas, fewer clinical breakthroughs can be highlighted. Laboratory research has improved our understanding of the biology, and especially the molecular genetics of this disease. Unfortunately, these successes highlight the difficulties in translating laboratory results into substantive clinical improvements. In part, these difficulties stem from a schizophrenic view of the development and evolution of brain tumors. We believe either that (1) brain tumors are local and therefore the most important research should have as its goal local control, or (2) brain tumors are diffuse, which is to say that the cells rapidly grow beyond their initial locus, and our research goal is the prevention or treatment of the advancing tumor front. Clearly both hypotheses have merit and, in fact, almost certainly, both are true. The question becomes, should we devote our research energies to one hypothesis at the exclusion of the other?
From the Barrow Neurological Institute, Phoenix, Ariz.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(4):493-495.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats
Iwadate et al.
Clin. Cancer Res. 2005;11:3821-3827.
ABSTRACT
| FULL TEXT
Cytokine Gene Therapy of Gliomas: Induction of Reactive CD4+ T Cells by Interleukin-4-transfected 9L Gliosarcoma Is Essential for Protective Immunity
Giezeman-Smits et al.
Cancer Res. 2000;60:2449-2457.
ABSTRACT
| FULL TEXT
Neuro-oncology 1999
Rosenberg
Arch Neurol 1999;56:397-398.
FULL TEXT
|
